| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2016035008 |
| Title |
Pyridopyrimidine Derivatives As Mek Inhibitors. |
| Abstract |
The present disclosure is related to heterocyclyl compounds as MEK inhibitors. These compounds include heterocyclyl compounds of formula (I), their pharmaceutically acceptable salts, their combinations with suitable medicaments, and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment. The compounds as disclosed herein are of Formula (I) below:(I). |
| Applicant(s) |
Lupin Limited |
| Representative Drug(s) |
D0PK6X |
Drug Info
|
IC50 < 500 nM |
[1] |
| Patent ID |
WO2016155473 |
| Title |
P-Toluenesulfonate for Mek Kinase Inhibitor, and Crystal form Thereof and Preparation Method Therefor. |
| Abstract |
Disclosed are a p-toluenesulfonate for an MEK kinase inhibitor, and a crystal form thereof and a preparation method therefor. Specifically, disclosed are a 2-((2-fluorine-4-iodophenyl)amino)-1-methyl-. |
| Applicant(s) |
Jiangsu Hengrui Medicine Co., Ltd |
| Representative Drug(s) |
D0KV2U |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2016011160 |
| Title |
Compositions for Treating Cancer Using Pd-1 Axis Binding Antagonists and Mek Inhibitors. |
| Abstract |
The present invention describes combination treatment comprising a PD- 1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. |
| Applicant(s) |
GENENTECH, INC. F. HOFFMAN-LA ROCHE AG |
| Patent ID |
WO2013019906 |
| Title |
Methods of Treating Cancer Using Pd-1 Axis Binding Antagonists and Mek Inhibitors. |
| Abstract |
The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer. |
| Applicant(s) |
Genentech, Inc |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US20160136150 |
| Title |
Compounds and Compositions As Inhibitors of Mek. |
| Applicant(s) |
Novartis |
| Representative Drug(s) |
D05VVZ |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US20160168103 |
| Title |
Preparation of and formulation Comprising A Mek Inhibitor. |
| Applicant(s) |
Array Biopharma |
| Representative Drug(s) |
D0DB3L |
Drug Info
|
N.A. |
Click to Show More |
[1] |
|
2
|
D0R8DW
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
US20160235721 |
| Title |
Benzoheterocyclic Compounds and Use Thereof. |
| Applicant(s) |
Shanghai Kechow Pharma |
| Representative Drug(s) |
D0A8KL |
Drug Info
|
IC50 = 100 to 1000 nM |
[1] |
| Patent ID |
US20160108041 |
| Title |
Substituted Pyridinone Compounds As Mek Inhibitors. |
| Applicant(s) |
Asan Foundation |
| Representative Drug(s) |
D01GWS |
Drug Info
|
IC50 < 500 nM |
[1] |
| Patent ID |
US20160002212 |
| Title |
Dual Mek/Pi3K Inhibitors and Therapeutic Methods Using The Same. |
| Applicant(s) |
The Regents of the University of Michigan |
| Patent ID |
US20150250762 |
| Title |
Novel Mek Inhibitors for Treating Cardiomyopathies and Related Conditions. |
| Applicant(s) |
Allomek Therapeutics |
| Representative Drug(s) |
D0J7DA |
Drug Info
|
IC50 < 100 nM |
[1] |
| Patent ID |
US20150141399 |
| Title |
Mek Inhibitors and Methods of Their Use. |
| Applicant(s) |
Exelixis |
| Representative Drug(s) |
D0K6HD |
Drug Info
|
IC50 < 50 nM |
[1] |
| European Patent Office (EPO) |
| Patent ID |
EP2984088 |
| Title |
Quinazolines and Azaquinazolines As Dual Inhibitors of Ras/Raf/Mek/Erk and Pi3K/Akt/Pten/Mtor Pathways. |
| Applicant(s) |
Asana Biosciences |
| Representative Drug(s) |
D03WFE |
Drug Info
|
IC50 = 100 to 1000 nM |
[1] |
| Japan Patent Office (JPO) |
| Patent ID |
JP2015078199 |
| Title |
N-(Arylamino)Sulfonamide Derivative Comprising Mek Inhibitor Polymorphous form, and Composition, Use Method and Method for Preparing The Same. |
| Applicant(s) |
Ardea Biosciences |
| Representative Drug(s) |
D0OR2V |
Drug Info
|
N.A. |
[1] |
